| Date Filed | Type | Description |
| 10/03/2023 |
4
| Boudes Pol F (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 61,676 options to buy
@ $1.66, valued at
$102.4k
|
|
| 10/03/2023 |
4
| Melincoff Gwen A (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 61,676 options to buy
@ $1.66, valued at
$102.4k
|
|
| 10/03/2023 |
4
| Bar-Shalev Amos (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 61,676 options to buy
@ $1.66, valued at
$102.4k
|
|
| 10/03/2023 |
4
| Ben Zvi Shmuel (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 61,676 options to buy
@ $1.66, valued at
$102.4k
|
|
| 10/03/2023 |
4
| Schwartz Aharon (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 61,676 options to buy
@ $1.66, valued at
$102.4k
|
|
| 08/17/2023 |
4
| Bashan Dror (President and CEO) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 800,000 shares
@ $0 |
|
| 08/17/2023 |
4
| Rubin Eyal (Sr. VP and CFO) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 201,903 shares
@ $0 |
|
| 08/17/2023 |
4
| Hayon Yael (VP, Research & Development) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 35,115 shares
@ $0
Granted 35,115 options to buy
@ $1.99, valued at
$69.9k
|
|
| 08/17/2023 |
4
| Naos Yaron (Sr. VP, Operations) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Granted 187,344 shares
@ $0 |
|
| 08/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 07/07/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 06/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/19/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/18/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/18/2023 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/05/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 02/27/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/27/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 02/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/27/2023 |
8-K
| Quarterly results |
| 02/24/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/05/2023 |
4
| Schwartz Aharon (Director) has filed a Form 4 on Protalix BioTherapeutics, Inc.|
Txns:
| Bought 110,000 shares
@ $1.4165, valued at
$155.8k
|
|
| 01/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 01/03/2023 |
SC 13G/A
| NACHT MARIUS reports a 5.3% stake in Protalix BioTherapeutics, Inc. |
| 12/27/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|